Site Editor

Thomas Flaig, MD

Advertisement

Advertisement

News

ESMO 2021: 3-Year Outcomes With Perioperative Chemotherapy Regimen for Muscle-Invasive Bladder Cancer

News

Nectin-4 Expression and Prognosis in Upper Tract Urothelial Cancer

Medical Literature

Case Report: Older Woman With Metastatic Bladder Cancer Responds to Pembrolizumab

News

Do Antibiotics Impact the Efficacy of Pembrolizumab in Metastatic Urothelial Carcinoma?

News

Pembrolizumab Receives Full FDA Approval for Certain Patients With Advanced Urothelial Carcinoma

News

Is Aspirin Intake Associated With Risk of Bladder Cancer or Its Prognosis?

Medical Literature

Are Lebanese and Jordanian Populations at Higher Risk for Bladder Cancer?

Monika Joshi, MD, on After the DUART Trial: Next Steps in Treating Urothelial Cancer of the Bladder

Sumanta K. Pal, MD: Does Adding Berzosertib to Chemotherapy Improve Outcomes in Urothelial Carcinoma?

View More

Advertisement

JNCCN Spotlights

Enfortumab Vedotin-ejfv

Sacituzumab Govitecan-hziy

View More

More

News

Can Dietary Tomato Intake Influence the Risk of Bladder Cancer?

AUA 2021: Long-Term Analysis of UGN-101 in Upper Tract Urothelial Carcinoma

Nectin-4 Expression and Prognosis in Upper Tract Urothelial Cancer

Preoperative Chemotherapy for Muscle-Invasive Bladder Cancer: Is Age Related to Response?

Adding Atezolizumab to Chemotherapy for Muscle-Invasive Bladder Cancer

FDA Approves Nivolumab as First Adjuvant Treatment for High-Risk Urothelial Carcinoma

AUA 2021: Antibody Levels as Predictors of Response to Immunotherapy in Bladder Cancer

Novel Approach to Detecting PD-L1 in the Urine of Patients With Bladder Cancer

View More

Advertisement

Published

Medical Literature

Combination Regimen Under Study in Metastatic Urothelial Carcinoma

Update on Managing Non–Muscle-Invasive Bladder Cancer

Can Leukocyte Telomere Length Predict Bladder Cancer Risk?

Bladder Urothelial Carcinoma: Is Age Related to Risk of Lymph Node Metastasis?

View More

Ongoing

CE Activities

Metastatic Urothelial Carcinoma: 2020 Multidisciplinary Molecular Tumor Board

Newly Approved Agents for Patients with Metastatic Urothelial Bladder Carcinoma Who Experience Disease Progression on Immune Checkpoint Inhibitor Therapy

Oncology Today with Dr Neil Love: Immune Checkpoint Inhibitors in Urothelial Bladder Carcinoma

Emerging Paradigms in Advanced/Metastatic Urothelial Cancer: What Are the Implications to Practice?

View More

Available

Clinical Trials

Early Intervention for Impairments Identified During Comprehensive Geriatric Assessment in Patients With Bladder Cancer

Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer

Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer

Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation

View More

Resources

For Your Patients

Bladder Cancer Advocacy Network

American Cancer Society

American Bladder Cancer Society

JNCCN: How To Manage Cancer Care During COVID-19 Pandemic

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2021 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.